Tocilizumab and other targeted therapies for severe cutaneous immune-related adverse events

Br J Dermatol. 2020 Oct;183(4):613. doi: 10.1111/bjd.19322. Epub 2020 Sep 6.

Authors

L L Thompson^{1

2}, S T Chen^{1

2

3}

Affiliations

¹ Harvard Medical School, Boston, MA, USA.
² Departments of, Department of, Dermatology, Massachusetts General Hospital, Boston, MA, USA.
³ Department of, Internal Medicine, Massachusetts General Hospital, Boston, MA, USA.

PMID: 32892364
DOI: 10.1111/bjd.19322

No abstract available

Publication types

Comment

MeSH terms

Antibodies, Monoclonal*
Antibodies, Monoclonal, Humanized* / adverse effects
Humans

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
tocilizumab